| 1 |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29.
|
| 2 |
中国抗癌协会大肠癌专业委员会专家组. 结直肠癌肝转移转化治疗中靶向药物合理应用的专家指导意见[J]. 中华胃肠外科杂志，2013, 16(10): 1000-1004.
|
| 3 |
Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases[J]. Eur J Cancer, 2006, 42(14): 2212-2221.
|
| 4 |
Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases[J]. Eur J Cancer, 2009, 45(17): 2947-2959.
|
| 5 |
Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J]. Ann Surg, 2005, 241(5): 722-724.
|
| 6 |
Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis[J]. Ann Surg Oncol, 2007, 14(2): 786-794.
|
| 7 |
Abdalla EK. Commentary: Radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology[J]. Am J Surg, 2009, 197(6): 737-739.
|
| 8 |
张甘露，赵长林. 结直肠癌肝转移新辅助治疗的进展[J]. 国际肿瘤学杂志, 2010, 37(11): 859-861.
|
| 9 |
Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J]. J Clin Oncol, 2007, 25(13): 1670-1676.
|
| 10 |
Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) asfirst-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J]. Br J Cancer, 2006, 94(6): 798-805.
|
| 11 |
Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis[J]. J Natl Cancer Inst, 2011, 103(1): 21-30.
|
| 12 |
Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial[J]. Lancet Oncol, 2010, 11(1): 38-47.
|
| 13 |
Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long-course neuxdjuvent chemoradiotherapy for locally advanced rectal cancer[J]. Histopathology, 2005, 47 (2): 141-146.
|
| 14 |
Edge SB, Byrd DD, Compton CC, et al. AJCC cancer staging manual[M]. 7th ed. New York: Springer-Verlag, 2010.
|
| 15 |
van Vledder MG, dejong MC, Pawlik TM，et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned?[J]. J Gastrointest Surg, 2010, 14(11): 1691-1700.
|
| 16 |
Zhao Changlin, Yang Yang, Huimian Xu, et al. Advances in multidisciplinary treatment of rectal cancer[J]. Clin Oncol Cancer Res, 2009, 6 (5): 367-373.
|
| 17 |
Rossi P, De Sanctis F, Ricciardi E, et al. Neoadjuvant radiochemotherapy in the multidisciplinary treatment of rectal cancer[J]. World J Surg Oncol, 2013, 2(3): 2277-3479.
|
| 18 |
Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases[J]. J Clin Oncol, 2006, 24(13): 2065-2072.
|
| 19 |
Kneuertz PJ, Maithel SK, Staley CA, et al. Chemotherapy-associated liver injury: impact on surgical management of colorectal cancer liver metastases[J]. Ann Surg Oncol, 2011, 18(1): 181-190.
|
| 20 |
Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases[J]. J Clin Oncol, 2006, 24(31): 4954-4955.
|
| 21 |
Chun YS, Laurent A, Maru D, et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases[J]. Lancet Oncol, 2009, 10(3): 278-286.
|
| 22 |
Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer[J]. N Engl J Med, 1999, 341(27): 2039-2048.
|
| 23 |
Kemeny N. Management of liver metastases from colorectal cancer[J]. Oncology (Williston Park), 2006, 20(10): 1161-1176, 1179.
|
| 24 |
Engstrom PF, Benson AB 3rd, Chen YJ, et al. Rectal cancer clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2005, 3(4): 492-508.
|
| 25 |
Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Oncol, 2007, 25(23): 3456-3461.
|
| 26 |
Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2+irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)[J]. Annals of Oncology, 2009, 20(4): 674-680.
|
| 27 |
Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases[J]. Ann Surg, 1997, 225(1): 51-62.
|
| 28 |
Meyer J, Czito B, Yin FF, et al. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy[J]. Clin Colorectal Cancer, 2007, 6(5): 348-356.
|
| 29 |
Andreou A, Brouquet A, Abdalla EK, et al. Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate[J]. HPB (Oxford), 2011, 13(11): 774-782.
|